| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN 37232; and 2Unité de Nutrition et Métabolisme Protéique, Institut National de la Recherche Agronomique, Centre de Recherches en Nutrition Humaine de Clermont-Fd, 63122 Ceyrat, France
Submitted 26 January 2004 ; accepted in final form 9 March 2004
Whether glucagon-like peptide-1 (GLP-1) has insulin-independent effects on glucose disposal in vivo was assessed in conscious dogs by use of tracer and arteriovenous difference techniques. After a basal period, each experiment consisted of three periods (P1, P2, P3) during which somatostatin, glucagon, insulin, and glucose were infused. The control group (C) received saline in P1, P2, and P3, the PePe group received saline in P1 and GLP-1 (7.5 pmol·kg–1·min–1) peripherally (Pe; iv) in P2 and P3, and the PePo group received saline in P1 and GLP-1 peripherally (iv) (P2) and then into the portal vein (Po; P3). Glucose and insulin concentrations increased to two- and fourfold basal, respectively, and glucagon remained basal. GLP-1 levels increased similarly in the PePe and PePo groups during P2 (
200 pM), whereas portal GLP-1 levels were significantly increased (3-fold) in PePo vs. PePe during P3. In all groups, net hepatic glucose uptake (NHGU) occurred during P1. During P2, NHGU increased slightly but not significantly in all groups. During P3, NHGU increased in PePe and PePo groups to a greater extent than in C, but no significant effect of the route of infusion of GLP-1 was demonstrated (16.61 ± 2.91 and 14.67 ± 2.09 vs. 4.22 ± 1.57 µmol·kg–1·min–1, respectively). In conclusion: GLP-1 increased glucose disposal in the liver independently of insulin secretion; its full action required long-term infusion. The route of infusion did not modify the hepatic response.
glucagon-like peptide-1; glucose uptake; portal infusion; dog
This article has been cited by other articles:
|
|
 |
|
  D. Zheng, V. Ionut, V. Mooradian, D. Stefanovski, and R. N. Bergman Portal glucose infusion-glucose clamp measures hepatic influence on postprandial systemic glucose appearance as well as whole body glucose disposal Am J Physiol Endocrinol Metab, February 1, 2010; 298(2): E346 - E353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Edgerton, K. M.S. Johnson, D. W. Neal, M. Scott, C. H. Hobbs, X. Zhang, A. Duttaroy, and A. D. Cherrington Inhibition of Dipeptidyl Peptidase-4 by Vildagliptin During Glucagon-Like Peptide 1 Infusion Increases Liver Glucose Uptake in the Conscious Dog Diabetes, January 1, 2009; 58(1): 243 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Dardevet, S. R Kimball, L. S Jefferson, A. D Cherrington, D. Remond, C. A DiCostanzo, and M. C. Moore Portal infusion of amino acids is more efficient than peripheral infusion in stimulating liver protein synthesis at the same hepatic amino acid load in dogs Am. J. Clinical Nutrition, October 1, 2008; 88(4): 986 - 996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Knauf, P. D. Cani, D.-H. Kim, M. A. Iglesias, C. Chabo, A. Waget, A. Colom, S. Rastrelli, N. M. Delzenne, D. J. Drucker, et al. Role of Central Nervous System Glucagon-Like Peptide-1 Receptors in Enteric Glucose Sensing Diabetes, October 1, 2008; 57(10): 2603 - 2612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Ionut, D. Zheng, D. Stefanovski, and R. N. Bergman Exenatide can reduce glucose independent of islet hormones or gastric emptying Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E269 - E277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Holst The Physiology of Glucagon-like Peptide 1 Physiol Rev, October 1, 2007; 87(4): 1409 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tsunekawa, N. Yamamoto, K. Tsukamoto, Y. Itoh, Y. Kaneko, T. Kimura, Y. Ariyoshi, Y. Miura, Y. Oiso, and I. Niki Protection of pancreatic {beta}-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies J. Endocrinol., April 1, 2007; 193(1): 65 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Ionut, I. F. Liberty, K. Hucking, M. Lottati, D. Stefanovski, D. Zheng, and R. N. Bergman Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action Am J Physiol Endocrinol Metab, October 1, 2006; 291(4): E779 - E785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Cani, C. Knauf, M. A. Iglesias, D. J. Drucker, N. M. Delzenne, and R. Burcelin Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like Peptide 1 receptor. Diabetes, May 1, 2006; 55(5): 1484 - 1490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Dardevet, M. C. Moore, C. A. DiCostanzo, B. Farmer, D. W. Neal, W. Snead, M. Lautz, and A. D. Cherrington Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors Am J Physiol Gastrointest Liver Physiol, November 1, 2005; 289(5): G806 - G814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Sancho, M. V Trigo, N. Gonzalez, I. Valverde, W. J Malaisse, and M. L Villanueva-Penacarrillo Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats J. Mol. Endocrinol., August 1, 2005; 35(1): 27 - 38. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
